Advanced Biologics publishes additional OsteoAMP® abstracts in The Bone and Joint Journal

News provided by

Jul 24, 2014, 10:28 ET

CARLSBAD, Calif., July 24, 2014 /PRNewswire/ -- Advanced Biologics, currently attending the NASS Summer Spine Meeting in Amelia Island, FL, announced today the publishing of two abstracts within The Bone and Joint Journal. Initially presented at the European Orthopaedic Research Society meeting, both abstracts further substantiate the differentiation and clinical benefit of OsteoAMP® allograft-derived growth factor.

The first abstract, "Osteoinductivity and osteogenicity of leading allograft bone products", examined the BMP-2 content and bone forming potential of OsteoAMP and Osteocel® Plus (Nuvasive). In this athymic rat study, products were implanted and assessed for bone formation and measurement of the cellular, mineral, and collagen phase content of BMP-2. Osteocel Plus exhibited increased osteonecrosis over all time periods and no BMP-2 from cells on ELISA analysis. OsteoAMP on the other hand displayed approximately 1000 times the BMP-2 amounts of Osteocel Plus and new bone formation and cellularity increase through all time points.

"Our goal of this paper was to validate the anecdotal evidence we hear on a daily basis from the field," commented Scott Cadotte, VP of Sales and Marketing at Advanced Biologics. "This showcases the superiority of OsteoAMP over a leading allogeneic stem cell product and at a more cost-effective price."

In the second abstract, "A blinded multi-centre, clinical and radiological study to evaluate the efficacy of OsteoAMP versus rhBMP-2in TLIF/LLIF procedures", a total of 254 consecutive patients (383 total levels) were treated with a TLIF or LLIF procedure and assessed radiologically. As has previously been shown, OsteoAMP produced faster fusion rates than rhBMP-2 and with much less radiologically evident adverse events such as osteolysis and ectopic bone formation.

OsteoAMP is an award winning allograft-derived growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic) and allograft-derived stem cells, such as Osteocel Plus or Trinity® Elite™ (Orthofix). OsteoAMP's three distinctive formats (granules, compressible sponges and putty) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.

About Advanced Biologics

Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC has been recognized three times as 'Best New Technology' during the Orthopedics This Week Spine Technology Awards.

www.advancedbiologics.com

SOURCE Advanced Biologics